CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project is developing a novel Antibody-Drug Conjugate (ADC) aimed at depleting macrophages in the tumor microenvironment, specifically targeting breast cancer and solid tumors. By reducing tumor-associated macrophages, the ADC seeks to enhance the effectiveness of cancer treatments and improve patient outcomes.
The project is focused on the development of a groundbreaking Antibody-Drug Conjugate (ADC) specifically designed for macrophage depletion in the Tumor Microenvironment (TME).
With a primary focus on breast cancer and solid tumors, this initiative represents a paradigm shift in cancer therapeutics.The presence of Tumor-Associated Macrophages (TAMs) in the TME has been identified as a significant factor in tumor progression and immune evasion.
Our proposed ADC will directly target these macrophag…
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
